Substance
ID:983
Names and Identifiers
Brand Name
ModrastaneDesopanModrenal
IUPAC name
(1S,2R,6R,8S,11S,12S,15S,16S)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.0^{2,8}.0^{6,8}.0^{12,16}]octadec-4-ene-4-carbonitrile
Synonyms
trilostaneTrilostane
IUPAC Traditional name
trilostane
Properties
Physical Property
Hydrophobicity(logP)
3
Molecule Details
Drug Groups
approved; withdrawn; investigational
Description
Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994. [Wikipedia]
Indication
Used in the treatment of Cushing's syndrome. It is normally used in short-term treatment until permanent therapy is possible.
Pharmacology
Trilostane blocks an enzyme involved in the production of several steroids including cortisol. Inhibiting this enzyme inhibits the production of cortisol. In Cushing's syndrome, the adrenal gland overproduces steroids. Although steroids are important for various functions of the body, too much can cause problems. Trilostane reduces the amount of steroids produced by the adrenal gland. This product was withdrawn from the U.S. market in April 1994.
Toxicity
Symptoms of overdose include darkening of skin, drowsiness or tiredness, loss of appetite, mental depression, skin rash, and/or vomiting.
Affected Organisms
Humans and other mammals
Biotransformation
Hepatic.
Half Life
8 hours.
References
•
Komanicky P, Spark RF, Melby JC: Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J Clin Endocrinol Metab. 1978 Nov;47(5):1042-51.
[Pubmed]
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
• Komanicky P, Spark RF, Melby JC: Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J Clin Endocrinol Metab. 1978 Nov;47(5):1042-51. Pubmed